Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).

Alejandro Ruiz-PatiñoOscar ArrietaAndrés Felipe CardonaClaudio MartínLuis E RaezZyanya L Zatarain-BarrónFeliciano BarrónLuisa RicaurteMaría A Bravo-GarzónLuis MasLuis CorralesLeonardo RojasLorena LupinacciFlorencia PerazzoCarlos BasOmar CarranzaCarmen PuparelliManglio RizzoRossana RuizChristian RolfoPilar ArchilaJuly RodríguezCarolina SoteloCarlos VargasHernán CarranzaJorge OteroLuis E PinoCarlos OrtízPaola LaguadoRafael Rosellnull null

Published in: Thoracic cancer (2019)

Patients who receive immune-checkpoint inhibitors as part of their treatment for NSCLC have better overall survival (OS) compared with matched patients treated with standard chemotherapy, regardless of the line of treatment.

Keyphrases

small cell lung cancer
squamous cell carcinoma
locally advanced
radiation therapy
rectal cancer
smoking cessation
tyrosine kinase